România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

haemopharm biofluids s.r.l. - italia - combinatii - sol. dial. perit. - preparate pentru dializa peritoneala produse hipertone

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

therdose pharma pvt. ltd. - irinotecanum - concentrat pentru solutie perfuzabila - 100 mg/5 ml

Uniunea Europeană - română - EMA (European Medicines Agency)

nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vaccinuri - profilaxia gripei cauzate de virusul a (h1n1) v 2009. celvapan ar trebui să fie utilizate în conformitate cu recomandările oficiale.

Uniunea Europeană - română - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpură, trombocitopenică, idiopatică - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 și 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 și 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Uniunea Europeană - română - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostate neoplasme - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.